Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-25
2005-10-25
Price, Elvis O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S019300, C514S064000, C536S017100, C544S229000, C530S322000
Reexamination Certificate
active
06958319
ABSTRACT:
The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1):in which Z1and Z2are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.
REFERENCES:
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 5106948 (1992-04-01), Kinder et al.
patent: 5169841 (1992-12-01), Kleeman et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5492900 (1996-02-01), LaHann
patent: 5574017 (1996-11-01), Gutheil
patent: 5780454 (1998-07-01), Adams et al.
patent: 5935944 (1999-08-01), LaHann
patent: 5990083 (1999-11-01), Iqbal et al.
patent: 6066730 (2000-05-01), Adams et al.
patent: 6083903 (2000-07-01), Adams et al.
patent: 6169076 (2001-01-01), Shull et al.
patent: 6297217 (2001-10-01), Adams et al.
patent: 6699835 (2004-03-01), Plamondon et al.
patent: 6713446 (2004-03-01), Gupta
patent: 2002/0169114 (2002-11-01), Gupta
patent: 2002/0188100 (2002-12-01), Plamondon et al.
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 00/57887 (2000-10-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 02/059130 (2002-01-01), None
patent: WO 02/059131 (2002-08-01), None
Ciechanover, “The Ubiquitin-Proteasome Proteolytic Pathway,”Cell, vol. 79, pp. 13-21 (Oct. 7, 1994).
Gennaro, “Remington: The Science and Practice of Pharmacy,” 20thEdition, Chapter 42, pp. 802-803 (2000).
Kataoka et al., “Totally Synthetic Polymer Gels Responding to External Glucose Concentration: Their Preparation and Application to On-Off Regulations of Insulin Release,”J. Am. Chem. Soc., 120:12694-12695 (1998).
Kibbe, “Handbook of Pharmaceutical Excipients,” 3rdEdition, pp. 324-328 (2000).
Korcek et al., “Absolute Rate Constants for the Autoxidation of Organometallic Compounds, Part II. Benzylboranes and 1-Phenylethylboranes,”J. Chem. Soc., Perkin Trans. II, pp. 242-248 (1972).
Richardson et al., “A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma,”N. Engl. J. Med., vol. 348, No. 26, pp. 2609-2617 (Jun. 2003).
Snyder et al., “Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes,”J. Am. Chem. Soc., 80, pp. 3611-3615 (1958).
Stella et al., “Development of Parenteral Formulations of Experimental Cytoxic Agents. I. Rhizoxin (NSC-332598),”International Journal of Pharmaceutics, vol. 43, pp. 191-199 (1988).
Williams et al., “The Effects of Cooling Rate on Solid Phase Transitions and Associated Vial Breakage Occurring in Frozen Mannitol Solutions,”Journal of Parenteral Science & Technology, vol. 40, No. 4, pp. 135-141 (Jul.-Aug. 1986).
Williams et al., “Vial Breakage by Frozen Mannitol Solutions: Correlation with Thermal Characteristics and Effect of Steroisomerism, Additives, and Vial Configuration,”Journal of Parenteral Science & Technology, vol. 45, No. 2, pp. 94-100 (Mar.-Apr. 1991).
Henry Michael C.
Leydig , Voit & Mayer, Ltd.
Price Elvis O.
The United States of America as represented by the Department of
LandOfFree
Formulation of boronic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation of boronic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation of boronic acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448014